Introduction {#S1}
============

Cigarette smoking and nicotine addiction continue to be major public health problems due to their established association with increased risk of cancer, respiratory disease, and many other disease outcomes in adults^[@R1]^. Cigarette smoking exposure also is highly deleterious to fetal development, having been associated with heightened risk of intrauterine growth restriction, low birth weight, stillbirth, and mortality^[@R2],[@R3],[@R4]--[@R8]^. Despite these adverse health outcomes for the smoker and the fetus carried by mothers who smoke, 8.4% of pregnant women continue to smoke while pregnant in the United States^[@R9]^. Accumulating evidence suggests *in utero* exposure to nicotine and other elements of cigarette smoking is associated with a greater risk of the subsequent development of mental illnesses^[@R10],[@R11]^. Components of cigarette smoke, including nicotine, have neuroteratogenic effects^[@R12]^, and there is mixed epidemiological evidence for maternal smoking during pregnancy as a risk factor for neuropsychiatric disorders including schizophrenia^[@R10],[@R11]^, attention-deficit / hyperactivity disorder^[@R13]--[@R17]^, Tourette syndrome^[@R17],[@R18]^, impaired cognitive development^[@R19],[@R20]^, obsessive-compulsive disorder^[@R17]^, and autism spectrum disorder^[@R21]^. Despite the potential ramifications of maternal smoking on the mental health of exposed offspring, little is known about the biological effects of smoke exposure on the developing human brain.

Possible molecular mechanisms underlying risk for neuropsychiatric disease from maternal smoking during pregnancy remain elusive. Previous studies have found epigenetic changes in cord blood^[@R22],[@R23]^ and differential gene expression in placental tissue^[@R24]^. However, only one prior study has directly examined associations of maternal smoking during pregnancy with epigenetic changes in the prenatal human brain^[@R25]^, and no study, to our knowledge, has characterized transcriptional changes in the prenatal brain. Characterizing the gene regulatory changes associated with smoking exposure in prenatal life may identify potential mechanisms related to disease risks later in life especially with regard to neuropsychiatric disorders. We can better understand the link between maternal smoking during pregnancy and future behavioral and cognitive sequelae by directly studying molecular changes in prenatal human cortical tissue exposed to cigarette smoke.

To characterize molecular changes in the developing prenatal brain associated with *in utero* smoking exposure, we first analyzed RNA-seq data from post-mortem fetal human prefrontal cortex tissue, contrasting exposed to unexposed prenatal tissue. Then to assess the developmental specificity of these molecular changes in the prenatal cortex, we did an analogous comparison of cortical gene expression between adult smokers to non-smokers. Lastly to ascertain the potentially age-dependent effects of smoking exposure on the cortex, we formally tested whether the effects of smoking exposure on gene expression were different on the developing brain compared to the adult brain. The results of these investigations highlight dysregulation of the developing prenatal cortex's transcriptome associated with *in utero* smoking exposure and their implications for possible mechanisms of risk for neurodevelopmental disorders later in life.

Results {#S2}
=======

Gene expression changes associated with smoking exposure in the developing brain {#S3}
--------------------------------------------------------------------------------

We performed differential expression analysis of genes and their transcript features comparing dorsolateral prefrontal cortex (DLPFC) tissue from 16 smoking-exposed compared to 17 smoking-unexposed prenatal samples ([Table 1](#T1){ref-type="table"}, for further details see [Results S1](#SD1){ref-type="supplementary-material"} and [Supplemental Table S1](#SD2){ref-type="supplementary-material"}). After correcting for multiple testing (at false discovery rate, FDR\<10%), 14 prenatal genes had evidence of differential expression (DE), mostly at the gene-level summarization ([Table 2](#T2){ref-type="table"}, median absolute log~2~ fold change \[LFC\] = 0.618). Some of these differentially expressed genes are potentially related to nicotine dependence or addiction more broadly: *KCNN2*, *GABRA4*, and *NRCAM* ([Figure 1A--C](#F1){ref-type="fig"}). The most significant differentially expressed transcript feature at the gene level was *KCNN2* which encodes a small-conductance Ca^2+^-activated K^+^ channel ([Figure 1A](#F1){ref-type="fig"}, p=2.60×10^−6^, LFC = −0.694). *GABRA4*, a gene coding for the alpha-4 subunit of the GABA receptor, was also differentially expressed ([Figure 1B](#F1){ref-type="fig"}, p=1.86×10^−5^, LFC = 1.06). *NRCAM*, a gene encoding neuronal cell adhesion molecule, was differentially expressed at the gene level ([Figure 1C](#F1){ref-type="fig"}, p=7.17×10^−5^, LFC = −0.568) and six previously annotated *NRCAM* exon-exon splice junctions were also differentially expressed (p~min~=2.29×10^−7^, LFC~p-min~= −0.689, [Supplemental Table S2](#SD2){ref-type="supplementary-material"}). Thus, prenatal smoking exposure is associated with changes in the expression of some genes previously associated with addiction in the literature.

Other differentially expressed genes between the exposed and unexposed prenatal groups play a role in neurodevelopment and may be linked to neuropsychiatric disorders: *CNTN4*, *EPHA8*, and *PCDH10* ([Figure 1D--F](#F1){ref-type="fig"}). Contactin 4 (*CNTN4,* [Figure 1D](#F1){ref-type="fig"}, p=2.79×10^−5^, LFC=0.682) is a cell adhesion molecule involved in synaptic formation^[@R26]^. The association with *PCDH10* was in a differentially expressed region ([Figure 1E](#F1){ref-type="fig"}, p=9.45×10^−8^, LFC= −1.37, chr4:134,116,962--134,116,976), a 15 base pair strictly intronic region. Protocadherin-10 (*PCDH10*) encodes a cell adhesion molecule involved in synaptic elimination^[@R27]^. EPH Receptor A8 (*EPHA8,* [Figure 1F](#F1){ref-type="fig"}, p=7.49×10^−6^~,~ LFC=1.55) encodes a member of the Eph family of tyrosine protein kinase receptors, which has a functional role in axonal pathfinding during neurodevelopment^[@R28]^. As a sensitivity analysis to further assess confounding by ethnicity (all 3 prenatal Caucasian samples were smoke-exposed), we undertook a subgroup analysis of the significant differentially expressed genes using only African-American prenatal samples (N=30). The resulting effect sizes were consistent with those from the original model supporting the robustness of these findings (*r*=0.99, p=1.18×10^−10^, [Supplemental Fig. S2](#SD1){ref-type="supplementary-material"}). These findings suggest, perhaps not surprisingly, that genes involved in neurodevelopment may be disrupted by prenatal exposure to cigarette smoke, a putative neurodevelopmental insult.

More subtle gene expression changes associated with smoking exposure in the adult brain {#S4}
---------------------------------------------------------------------------------------

In the adult sample, only two genes were differentially expressed between active smoker (N=57) and non-smoker groups (N=150; [Table 1](#T1){ref-type="table"}). *MARCO*, an immune gene, was the most significantly differentially expressed gene among adults ([Figure 2A](#F2){ref-type="fig"}; p=4.67×10^−9^, LFC = −1.603). We used a different cohort of DLPFC tissue from 107 patients with schizophrenia (65 active smokers, 42 non-smokers) to assess the replicability of this differential gene expression in adults. *MARCO* was similarly differentially expressed in this cohort (p=3.28×10^−5^, LFC = −1.34, [Figure 2B](#F2){ref-type="fig"}). To assess the robustness of our model, we then stratified adult smokers into three categories: non-smokers (N=150), light-smokers (N=23), and heavy smokers (N=23), based on cotinine levels (200 ng/mL heavy-light threshold). Under this ordinal sensitivity model, *MARCO* remained significantly differentially expressed (p=6.16×10^−10^~,~ LFC=−1.211, [Figure 2C](#F2){ref-type="fig"}), and our global results were highly correlated across all transcript feature-levels confirming the robustness of our analysis ([Supplemental Fig. S3](#SD1){ref-type="supplementary-material"}). An exon-exon splice junction mapping to four transcripts of *CEP85* (chr1:26,595,127--26,595,950) was also differentially expressed between adult smokers and non-smokers (p=4.46×10^−7^, LFC = −0.25), but this association did not replicate in our independent schizophrenia cohort (p=0.47, [Supplemental Fig. S4](#SD1){ref-type="supplementary-material"}). Together, these findings indicate cigarette smoke exposure has subtler effects on the adult prefrontal cortex's transcriptome than on the developing brain, despite having the larger sample size compared with the fetal cohort.

Significant changes in susceptibility to smoking exposure across development {#S5}
----------------------------------------------------------------------------

After observing non-overlapping genes within the differentially expressed transcript features across the adult and prenatal cohorts associated with smoking exposure, we performed an interaction analysis to more formally determine the potentially age-dependent effects of smoking exposure in prenatal versus adult samples. While the significant main effects of smoking exposure in adulthood were limited to *MARCO* and the *CEP85* junction described above, there were 5,293 differentially expressed features corresponding to 1,315 Ensembl genes ([Supplemental Table S3](#SD2){ref-type="supplementary-material"}) associated with the interaction between developmental stage (pre- versus post-natal) and smoking exposure after adjusting for possible technical and biological confounds (FDR\<10%). The different feature type analyses offer multiple lines of evidence for genes implicated as interaction genes (i.e., genes that respond differently to cigarette smoking in prenatal vs. adult cortical tissue), suggesting transcript-feature level analysis beyond the gene-level summary offer additional insight into changes in the transcriptomic landscape. For instance, 87 genes were shared as significant interaction genes across all feature types, but 315 genes were solely significant for an interaction effect at the exon-level summarization ([Figure 3](#F3){ref-type="fig"}).

We next asked whether smoking exposure's differential effects on gene expression across the lifespan are mostly driven by significant changes in the prenatal cortical transcriptome, hypothesizing that the prenatal cortical transcriptome is more pliable than the adult one. Post-hoc analysis confirmed that more of these transcript features with a significant interaction were nominally differentially expressed (p\<0.05) by smoking exposure in prenatal cortex (N=1,850, 35.0%) than in adult cortex (N=585, 11.1%; p=1.40×10^−8^). These findings underscore that smoking exposure exerts different effects on gene expression across the human lifespan and these effects occur more frequently in the prenatal cortex.

Enrichment of interaction genes in diverse processes and neurodevelopmental disorders {#S6}
-------------------------------------------------------------------------------------

To explore the potential functional implications of the 1,315 genes with differential effects of cigarette smoke exposure in prenatal and adult life, we performed gene ontology and pathway analyses with the sets of genes tagged by differentially expressed age-dependent transcript features: genes (N=752), exons (N=746), junctions (N=257), and ERs (N=285). We uncovered significant enrichment of biological categories across all ontologies tested ([Supplemental Table S4](#SD2){ref-type="supplementary-material"}).

Here, "nicotine addiction" (hsa05033, p=2.04×10^−7^, q=3.15×10^−5^) was one of the most significantly enriched KEGG categories across multiple feature summarizations. Other top KEGG categories included "retrograde endocannabinoid signaling" (hsa04723, p=2.04×10^−7^, q=3.15×10^−5^) and "neuroactive ligand-receptor interaction" (hsa04080, p=2.04×10^−7^, q=3.15×10^−5^). The most significantly enriched biological processes involved "behavior" (GO:0007610, p=2.33×10^−10^, q=9.87×10^−7^), "positive regulation of nervous system development" (GO:0051962, p=1.31×10^−7^, q=2.32×10^−4^), and "synapse organization" (GO:0050808, p=2.84×10^−7^, q=2.57×10^−4^). Interestingly, using disease ontology (DO) enrichment analyses, where pre-defined gene sets are based on prior disease associations in the literature, rather than biological function/pathways, the top enriched disease ontologies (DO) were related to autism spectrum disorder (ASD), including gene sets "autism spectrum disorder" (DOID:0060041, p=8.45×10^−8^, q=2.57 ×10^−5^), "autistic disorder" (DOID:12849, p=8.45×10^−8^, q=2.57 ×10^−5^), and "pervasive developmental disorder" (DOID:0060040, p=1.25×10^−7^, q=2.57 ×10^−5^).

After observing the DO enrichment related to autism and relevant molecular processes, we performed targeted enrichment analyses using publicly available autism spectrum disorder (ASD) gene databases^[@R29]^ and previously constructed neurodevelopmental gene sets^[@R30]^ to better determine sensitivity and specificity of the ASD gene set enrichments. In prenatal samples, this ASD enrichment was driven by *IL1RAPL2*, *GABRA4*, *CNTN4*, *NRCAM*, and *PCDH10* being differentially expressed ([Table 1](#T1){ref-type="table"}, N=5/14 SFARI genes, p=3.79×10^−4^, [Supplemental Table S5A](#SD2){ref-type="supplementary-material"}). We further observed enrichment of significant age-dependent interaction genes across multiple autism gene sets including SFARI Gene (p=7.20×10^−8^), AutDb (p=1.17×10^−7^), and the curated non-syndromic ASD gene database set (p=3.77×10^−4^, [Supplemental Table S5B](#SD2){ref-type="supplementary-material"}). We undertook a parallel analysis of smoking-unexposed cortical samples across the lifespan (prenatal vs. adult) to identify neurodevelopmentally regulated genes and contextualize the results ([Results S3](#SD1){ref-type="supplementary-material"}). We found that gene expression patterning over cortical development is similarly enriched for neuropsychiatric disease gene sets; mirroring the enrichment results with age-dependent interaction genes: the greatest enrichment was for ASD gene sets ([Supplemental Table S5C](#SD2){ref-type="supplementary-material"}). Interaction genes were less significantly enriched for schizophrenia genes implicated from single nucleotide variant (SNV) studies (p=0.00136), and only nominally significantly enriched for intellectual disability genes (p=0.0115) and syndromic neurodevelopmental disorder (NDD) genes (p=0.0175; [Supplemental Table S5B](#SD2){ref-type="supplementary-material"}). The enriched NDD (N=6) were a subset of the enriched ASD genes, but the enriched schizophrenia SNV and intellectual disability genes were mostly distinct ([Supplemental Fig. S5](#SD1){ref-type="supplementary-material"}). Therefore, genes affected differently by cigarette smoke exposure across the lifespan appear enriched in autism spectrum disorder and other neuropsychiatric disorders gene sets.

Smoking exposure's transcriptomic pattern is similar to post-mortem brain ASD case-control differences {#S7}
------------------------------------------------------------------------------------------------------

Next, to more fully interrogate these genes in ASD, we performed gene set enrichment analysis in post-mortem human brain tissue from a public database of patients with ASD compared to unaffected controls^[@R31]^ by comparing the gene expression differences from our significant differentially expressed prenatal and interaction genes against ASD-related gene expression differences ([Supplemental Table S6](#SD2){ref-type="supplementary-material"}, [Supplemental Fig. S6A](#SD1){ref-type="supplementary-material"}). Differentially expressed prenatal genes (N=14) were more highly ranked relative to other genes in terms of the ASD case-control differences in frontal cortex (BA9; p=1.35×10^−6^) and temporal cortex (BA41--42-22; p=6.49×10^−5^), but not vermis (p=0.646, [Supplemental Fig. S6B](#SD1){ref-type="supplementary-material"}). Likewise, the interaction genes tested in this ASD data (N=1,293) also showed significant enrichment for ASD case-control differences in frontal cortex (p=3.45×10^−5^) and temporal cortex (p=2.77×10^−9^), but not vermis (p=0.963, [Supplemental Fig. S6C](#SD1){ref-type="supplementary-material"}). We further found enrichment of these sets of genes among known protein-protein interactions ([Results S2](#SD1){ref-type="supplementary-material"}, [Supplemental Figure S7](#SD1){ref-type="supplementary-material"}). We did not observe significant enrichment for schizophrenia case-control differences^[@R32],[@R33]^ with either the differentially expressed prenatal genes (p=0.14) or the interaction genes (p=0.23). These findings suggest molecular changes in the developing human cortex associated with maternal smoking during pregnancy are related at the transcriptomic scale to the cortical pathology of ASD (i.e. these genes are differentially expressed as a group in a comparison of ASD samples to controls from a separate study), and these differences are at least partially selective.

Discussion {#S8}
==========

This study is the first, to our knowledge, to perform an extensive interrogation of the effect of smoking exposure on the prenatal cortical transcriptome. The prenatal brain is more sensitive to many environmental agents in both human and animal studies than the adult brain^[@R34]--[@R36]^. Therefore, one might expect signatures of smoking exposure would be more pronounced in the developing human brain. Consistent with this hypothesis, we found 14 genes differentially expressed in the prenatal cortex compared to only 2 genes in the adult cortex. Likewise, developmentally regulated genes were more affected by smoke-exposure during prenatal life than adulthood. The transcriptomic effects of smoking exposure were more noticeable in the prenatal cortex despite the smaller sample size available, underscoring the effects of maternal smoking on the prenatal human brain's sensitive developmental trajectory.

Prenatal exposure was associated with changes in gene expression relevant to neurodevelopment and addiction which some studies have linked to maternal smoking during pregnancy^[@R37]--[@R39]^. *NRCAM* encodes a neuronal cell adhesion molecule, and expression was reduced within smoking-exposed prenatal brain. This differential expression may have downstream consequences, as neuronal cell adhesion molecules are involved in neurodevelopment^[@R40]--[@R42]^ and have been linked to autism^[@R43]--[@R45]^ and schizophrenia^[@R46]--[@R48]^. *KCNN2* levels were also reduced in the smoking-exposed prenatal group. *KCNN2* encodes small conductance Ca^2+^-activated K^+^ channels, and is part of a family of proteins that has been linked to substance abuse^[@R49],[@R50]^.

Smoking exposure was also associated with changes in prenatal expression of multiple genes important in neurodevelopment such as *CNTN4* and *EPHA8* as well as components of the GABAergic signaling pathway ([Discussion S1](#SD1){ref-type="supplementary-material"}). Genes that were differentially expressed by smoking exposure in prenatal but not adult donors and vice versa were preferentially involved in processes relevant to neurodevelopment, such as synapse organization. Consistent with the neurodevelopmental origins of ASD, smoking-associated age-dependent and prenatal genes were enriched in publicly available autism spectrum disorder (ASD) gene databases and were differentially expressed as a group in an ASD case-control^[@R31]^ quality-corrected^[@R33]^ analysis. This intriguing finding was statistically robust and relatively specific to ASD, which may reflect a relatively greater role for disruptions to early brain development in ASD etiology compared to other severe mental illnesses such as bipolar disorder. Moreover, these enrichment result are consistent with the greater enrichment for ASD genes in preferentially prenatal expressed genes compared to other neuropsychiatric disorders^[@R30]^, and a parallel analysis likewise indicates developmentally regulated genes are highly enriched for ASD. Given the limited findings of smoking-associated differential expression in adults and the fact that adults are the sample population in many ASD studies, we do not believe this enrichment reflects possible confounding in ASD studies of gene expression in brain by smoking at the time of death. Furthermore, schizophrenia patients smoke at a much higher rate than the non-psychiatric population---studies of schizophrenia are often more confounded by smoking than ASD studies---but we observed only modest enrichment for schizophrenia genes. Our findings add orthogonal molecular support to the hypothesis that maternal smoking during pregnancy may be a risk factor for neuropsychiatric disease later in life, especially for ASD.

Regardless of age, differentially expressed genes between the smoking exposed and unexposed donors could also relate to other hazardous chemicals besides nicotine, indirect effects of cigarette smoke exposure, and residual confounding by unmeasured factors associated with smoking. Post-mortem brain studies, such as this one, are liable to confounding by various factors (e.g. RNA quality, age, sex, and race), but our exploratory analysis suggests these confounds are unlikely to be responsible for the gene expression differences. Furthermore, we constructed surrogate variables that capture transcriptomic variance driven by hidden confounds and adjusted for these in our analyses which improved our power to detect differential expression. Cigarette smoke contains over 500 distinct chemicals of which 98 have been deemed dangerous to human health^[@R51]^ and the molecular correlates of these compounds in human brain range in characterization. The genes identified in this study as differentially expressed by smoking exposure likely include ones that predispose to cigarette smoking susceptibility as well as ones that are altered by smoking or other related exposures. Nonetheless, these differentially expressed genes highlight genes and pathways that represent smoking-related changes in the developing brain.

Our results in DLPFC may not translate to other brain regions, as the effects of cigarette smoke exposure on the developing human cortex may vary across brain regions which have distinct cell type compositions and unique molecular profiles^[@R52]^. Moreover, our prenatal cohort includes mostly first trimester fetal brains, and the effects of smoking-exposure may differ in later prenatal cortical development. Future studies should seek to determine the molecular signature of cigarette smoke exposure across multiple developing brain regions and later time periods to refine the transcriptomic footprint of exposure in the developing human cortex. Finally, the temporality and relative contributions of genes and the environment, particularly the intrauterine environment^[@R53]^, on the observed molecular differences deserves further attention. Untangling the extent by which maternal smoking during pregnancy relates to a greater genetic burden for nicotine dependence subsequently inherited by the neonate^[@R54]--[@R56]^ compared to direct environmental or epigenetic insults^[@R57]^ warrants further portioning. Here, comprehensive expression quantitative trait loci mapping may help disentangle the functional consequences of predisposing genetic risk for nicotine dependence from the environmental effect of cigarette smoke exposure.

In summary, we performed transcriptome-wide scans to search for disturbances in gene expression associated with *in utero* smoking exposure and to understand the possible implications of gene dysregulation. The effect of smoking exposure on gene expression was more prominent in the developing prenatal brain than the mature adult brain. Disrupted neurodevelopment due to early environmental insults confers risk for neuropsychiatric disorders later in life, and indeed maternal smoking during pregnancy has been suggested as a risk factor for neuropsychiatric disorders in affected offspring^[@R10],[@R11]^. Our study provides molecular evidence that maternal smoking during pregnancy may disrupt pathways relevant in neurodevelopment, and potentially influence risk of neuropsychiatric disease in offspring---particularly autism spectrum disorder. Overall, these findings offer new molecular clues into how *in utero* smoking exposure may disrupt human cortex development and increase risk for the development of neuropsychiatric disorders in the offspring.

Materials and Methods {#S9}
=====================

Sample information: {#S10}
-------------------

We used a subset of postmortem human brain samples with RNA-sequencing data (N=240) described in Jaffe el al.^[@R32]^ to investigate the molecular correlates of smoke exposure across the lifespan. Smoking exposure was determined by nicotine and cotinine levels quantified via LC/MS-MS for the majority of samples ([SI Appendix](#SD1){ref-type="supplementary-material"}).

RNA-sequencing data processing: {#S11}
-------------------------------

Four convergent measurements of expression ("feature summarizations") were used to comprehensively assess the transcriptome: gene, exon, exon-exon splice junction, and expressed regions^[@R58]^ ([SI Appendix](#SD1){ref-type="supplementary-material"}). We retained genes, exons, and junctions with at least 10% or more of samples having at least 1 count per million (cpm), with at least partially annotated. Expressed regions (ERs) were defined by contiguous sequences with mean library-size normalized coverage \> 5 reads per 80 million^[@R58]^.

Differential expression: {#S12}
------------------------

Features were tested under an empirical Bayes framework for differential expression using the moderated t-test implemented in the *limma*^[@R59]^. Surrogate variables (SVs) were constructed using *sva*^[@R60]^ and were included as covariates to mitigate latent confounding ([Results S4](#SD1){ref-type="supplementary-material"}). Tested features with a false discovery rate (FDR) below 10% were considered differentially expressed (DE). $$y_{ij} = \alpha_{i} + \beta_{i}Smoke_{j} + \delta_{i}Age_{j} + \zeta_{i}RIN_{j} + t_{i}chrM_{j} + \kappa_{i}GAR_{j} + \theta_{i}MDS_{j} + \omega_{i}SV_{j} + \mu_{i}Sex_{j} + \varepsilon_{ij}$$ for feature *i* and donor *j* and binary smoking exposure *Smoke~j~*, adjusting for age, RNA Integrity Number (RIN), the proportion of reads aligning to chrM (a proxy for RNA quality), gene assignment rate (GAR, a proxy for RNA quality), the first MDS component (ancestry), surrogate variables (SVs), and the sex for each donor.

A sensitivity analysis was done with adult samples by stratifying smokers into heavy and light smokers (200 ng/mL cotinine cutpoint) and using testing the ordinal variable for differential expression (non-smoker \< light smoker \<heavy smoker). Replication, defined as p\<0.05 and same directionality of effect, of DE in adults was assessed using an independent cohort of 107 patients diagnosed with schizophrenia.

Gene set enrichment: {#S13}
--------------------

For gene set enrichment, transcript features were mapped to Entrez IDs and subsequently to six different gene ontologies (GO): KEGG^[@R61]^, GO-BP^[@R62]^, GO-MF^[@R62]^, GO-CC^[@R62]^, DO^[@R63]^, and Reactome^[@R64],[@R65]^. We tested for enrichment in each ontology with the hypergeometric test for overrepresentation implemented in *clusterProfiler*^[@R66]^. Enrichment of DE genes in curated gene sets was tested using Fisher's Exact Test.

Publicly available autism data: {#S14}
-------------------------------

We reprocessed reads from Parikshak et al.^[@R31]^ and tested for autism spectrum disorder (ASD) case-control gene expression differences, analogous to our procedure here ([SI Appendix](#SD1){ref-type="supplementary-material"}). The *geneSetTest* function in *limma* was used to competitively test whether sets of genes differentially expressed by smoking exposure were differentially expressed by ASD status, separately by brain region.

Protein-protein interaction: {#S15}
----------------------------

To create protein-protein interaction (PPI) networks, gene symbols were mapped to unique identifiers in the STRING (v. 10)^[@R67]^ database (STRING score\>400, homo sapiens). Functional association networks were then constructed on the basis of corresponding PPI scores.
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![Representative differentially expressed prenatal genes. \[RPKM: reads per kilobase per million\]. Normalized expression levels for six genes with significant (FDR\<10%, moderated t-test) differential expression are shown for smoking unexposed (N=17) and exposed (N=16) prenatal prefrontal cortex samples. These representative genes have been previously implicated in neurodevelopment and neuropsychiatric disease.](nihms-976894-f0001){#F1}

![**A.** *MARCO* expression in original model across development. \[RPKM: reads per kilobase per million\]. *MARCO* (Macrophage Receptor With Collagenous Structure) expression was reduced in adult smokers (N=57) compared to non-smokers (N=150). **B.** *MARCO* expression in the schizophrenia replication sample. *MARCO* expression was significantly reduced in smokers (N=65) compared to non-smokers (N=42) in a separate sample of schizophrenics collected, processed, analyzed with the same pipeline as the adult controls. **C.** *MARCO* expression under a sensitivity model in adult non-psychiatric controls (N=196). *MARCO* expression was inversely proportional to smoking intensity under our sensitivity ordinal model in which we stratified smokers into light (N=23) and heavy (N=23) smokers.](nihms-976894-f0002){#F2}

![Venn diagram of differentially expressed gene overlap by feature level summarization. 87 genes are implicated across all feature level summarizations (genes, exon-exon junctions, expressed regions, and exons). Other genes are tagged solely by our feature level analysis such as the 56 genes that were only identified as differentially expressed regions and not by other feature-level summarizations.](nihms-976894-f0003){#F3}

###### 

Description of sample characteristics.

                                             Prenatal                                            Adult (non-psychiatric)                                                        
  ------------------------------------------ --------------------------------------------------- ------------------------- ---------------------------------------------------- -------------------
  **N**                                      17                                                  16                        150                                                  57
  **Age**                                    17.36 (2.20) pcw^[†](#TFN1){ref-type="table-fn"}^   19.81 (5.19) pcw          41.46 (15.79) yrs^[‡](#TFN2){ref-type="table-fn"}^   42.48 (14.92) yrs
  **Race**                                                                                                                                                                      
      Caucasian                              0 (0.0%)                                            3 (18.8%)                 76 (50.7%)                                           22 (38.6%)
      African American                       17 (100.0%)                                         13 (81.2%)                74 (49.3%)                                           35 (61.4%)
  **Male**                                   10 (58.8%)                                          5 (31.2%)                 108 (72.0%)                                          40 (70.2%)
  **Source**                                                                                                                                                                    
      NIMH                                   0 (0.0%)                                            0 (0.0%)                  124 (82.7)                                           55 (96.5)
      Stanley                                0 (0.0%)                                            0 (0.0%)                  12 (8.0)                                             2 (3.5)
      UMB                                    17 (100.0%)                                         16 (100.0%)               14 (9.3)                                             0 (0.0)
  **RIN** [\*](#TFN3){ref-type="table-fn"}   8.82 (1.35)                                         8.94 (0.99)               8.33 (0.67)                                          8.52 (0.52)

preconception weeks

years

RNA Integrity Number

###### 

Significant differentially expressed genes between smoke exposed and unexposed human brain cortices in prenatal and adult cohorts (FDR\<10%).

             Prenatal     Adult                                                                                     
  ---------- ------------ ------------------------------------------------- -------- ------- -------- ------------- --------------
  Prenatal   *PCDH10*     Expressed Region                                  −1.367   0.026   −0.114   1             5.87×10^−4^
  Prenatal   *KCNN2*      Gene                                              −0.694   0.047   −0.015   0.991         1.65×10^−5^
  Prenatal   *EPHA8*      Gene                                              1.546    0.048   −0.019   0.993         2.54×10^−5^
  Prenatal   *TENM3*      Gene                                              0.804    0.048   −0.006   0.996         2.79×10^−11^
  Prenatal   *IL1RAPL2*   Gene                                              −1.036   0.048   −0.06    0.991         2.43×10^−4^
  Prenatal   *MPPED1*     Gene                                              0.385    0.051   −0.005   0.995         1.96×10^−5^
  Prenatal   *GABRA4*     Gene                                              1.059    0.056   0.031    0.987         8.82×10^−16^
  Prenatal   *ECHDC2*     Gene                                              0.864    0.056   0.015    0.993         3.21×10^−7^
  Prenatal   *SDC1*       Gene                                              0.367    0.056   0.092    0.978         0.455
  Prenatal   *CNTN4*      Gene                                              0.682    0.056   0.003    0.997         1.63×10^−8^
  Prenatal   *CHSY3*      Gene                                              0.55     0.063   0.02     0.991         2.82×10^−8^
  Prenatal   *RNF13*      Gene                                              −0.28    0.063   0.015    0.991         0.191
  Prenatal   *ZNF608*     Gene                                              0.343    0.067   0.035    0.991         0.013
  Prenatal   *NRCAM*      Gene, Junction^[b](#TFN5){ref-type="table-fn"}^   −0.568   0.1     0.014    0.991         1.27×10^−5^
  Adult      *MARCO*      Gene                                              0.896    0.432   −1.603   8.44×10^−5^   1.53×10^−4^
  Adult      *CEP85*      Junction                                          −0.054   0.939   −0.253   0.061         0.042

False discovery rate.

*NRCAM* gene level results presented here. For exon-exon splice junction results see [Supplemental Table S2](#SD2){ref-type="supplementary-material"}.

[^1]: Author contributions:

    S.A.S -- performed analyses and led the writing of the manuscript

    L.C. T. -- performed analyses and contributed to the writing of the manuscript

    C.A.M, L.J.B., B.S.M., E.O.J. -- contributed to the interpretation of the results and writing of the manuscript

    J.H.S. -- performed data generation

    A.D. -- performed clinical reviews and oversaw assessment of toxicology

    R.T. -- performed RNA extractions

    M.H. -- generated nicotine and cotinine data

    T.M.H. -- performed tissue dissections, contributed to the study design, interpretation of the results, and writing of the manuscript

    D.R.W. -- contributed to the study design, interpretation of the results, and writing of the manuscript

    D.B.H. -- contributed to the study design, statistical analyses, interpretation of the results, and writing of the manuscript

    J.E.K., A.E.J -- co-led the study, including the design, statistical analyses, interpretation, and writing of the manuscript
